HC Wainwright Forecasts Delcath Systems FY2029 Earnings

Delcath Systems, Inc. (NASDAQ:DCTH) – Equities research analysts at HC Wainwright issued their FY2029 EPS estimates for Delcath Systems in a research note issued on Friday, March 7th. HC Wainwright analyst S. Ramakanth anticipates that the company will earn $1.58 per share for the year. HC Wainwright has a “Buy” rating and a $24.00 price objective on the stock. The consensus estimate for Delcath Systems’ current full-year earnings is ($0.79) per share.

Separately, Craig Hallum boosted their price objective on Delcath Systems from $18.00 to $21.00 and gave the company a “buy” rating in a report on Friday, January 17th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $22.75.

Delcath Systems Stock Down 0.1 %

Shares of NASDAQ DCTH opened at $11.80 on Monday. The business’s 50 day moving average is $14.41 and its two-hundred day moving average is $11.77. Delcath Systems has a 52-week low of $3.70 and a 52-week high of $16.97. The firm has a market cap of $377.29 million, a price-to-earnings ratio of -8.74 and a beta of 0.82.

Delcath Systems (NASDAQ:DCTH) last issued its quarterly earnings data on Thursday, March 6th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.01). Delcath Systems had a negative return on equity of 338.16% and a negative net margin of 150.70%. The company had revenue of $15.10 million during the quarter, compared to analyst estimates of $14.96 million. During the same quarter in the prior year, the company posted ($0.48) earnings per share.

Institutional Investors Weigh In On Delcath Systems

Hedge funds have recently added to or reduced their stakes in the business. Jefferies Financial Group Inc. acquired a new position in shares of Delcath Systems in the fourth quarter worth $251,000. Palisades Investment Partners LLC boosted its holdings in Delcath Systems by 13.1% in the fourth quarter. Palisades Investment Partners LLC now owns 169,327 shares of the company’s stock valued at $2,039,000 after purchasing an additional 19,671 shares during the period. PharVision Advisers LLC acquired a new position in Delcath Systems during the 4th quarter worth $129,000. Soleus Capital Management L.P. purchased a new stake in Delcath Systems during the 4th quarter worth about $9,644,000. Finally, Squarepoint Ops LLC raised its position in Delcath Systems by 56.3% in the 4th quarter. Squarepoint Ops LLC now owns 79,537 shares of the company’s stock valued at $958,000 after purchasing an additional 28,662 shares in the last quarter. 61.12% of the stock is currently owned by institutional investors and hedge funds.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.